Skip to main content

Hybrigenics Closes 16.8M in Series C Financing

NEW YORK, April 12 - French functional proteomics company Hybrigenics today said it has pocketed €16.8 million, or roughly $14.8 million, in a Series C round of venture capital financing.

The financing, which brings Hybrigenics' total take to €47 million, will be used to bolster its therapeutic-target validation, emphasizing infectious-diseases drug discovery. The funds will also help support Hybrigenics' internal and external growth, and to reinforce its international business presence, it said.

Life Sciences Partners, in the Netherlands and Germany, led the round.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.